Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Nature Medicine
|
May 6, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2018
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, et al.
Neuro-Oncology Practice
|
February 7, 2025
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Vincent Fougner, Thomas Urup, Hans Skovgaard Poulsen, et al.
Frontiers in Oncology
|
March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapies
Christin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
BMC Cancer
|
August 7, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
Kristian Egebjerg, Iben Spanggaard, Lise Barlebo Ahlborn, et al.
BMC Cancer
|
March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Gynecologic Oncology
|
January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
The Lancet. Oncology
|
May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
BMC Cancer
|
February 23, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, et al.
Advanced Healthcare Materials
|
November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
Maria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Nature Medicine
|
May 6, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2018
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, et al.
Neuro-Oncology Practice
|
February 7, 2025
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Vincent Fougner, Thomas Urup, Hans Skovgaard Poulsen, et al.
Frontiers in Oncology
|
March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapies
Christin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
BMC Cancer
|
August 7, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
Kristian Egebjerg, Iben Spanggaard, Lise Barlebo Ahlborn, et al.
BMC Cancer
|
March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Gynecologic Oncology
|
January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
The Lancet. Oncology
|
May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
BMC Cancer
|
February 23, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, et al.
Advanced Healthcare Materials
|
November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
Maria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Page
of 4